RARA and cancer: Initial studies from Wang and coworkers reported that all-trans retinoic acid (ATRA) and other retinoic acid receptor alpha (RARalpha) agonists markedly impaired NRF2-dependent induction of ARE-driven genes by cancer chemopreventive agents but not its nuclear translocation in human breast cancer MCF-7 cells [347] (see Table 2).